Drug development pipeline · CancerIndex

Drugs

347 approved drugs

Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).

Drug	Stage	Max phase	Active	Recruiting	Phase 3	Total trials	Approvals	Jurisdictions	First approval	First trial
Pembrolizumab	Approved	Phase 4	969	471	309	2,150	148	CA, EU, US	Sep 4, 2014	Aug 26, 2010
Cyclophosphamide	Approved	Phase 4	703	369	500	2,823	43	CA, US	Nov 16, 1959	1987-08
Carboplatin	Approved	Phase 4	671	337	543	2,361	13	CA, US	Dec 31, 1994	1988-03
Cisplatin	Approved	Phase 4	604	294	672	2,478	16	CA, US	Dec 19, 1978	1988-04
Paclitaxel	Approved	Phase 4	520	253	562	2,290	39	CA, EU, US	Oct 31, 2001	1988-05
Nivolumab	Approved	Phase 4	487	187	150	1,391	98	CA, EU, US	Dec 22, 2014	2006-08
Bevacizumab	Approved	Phase 4	439	248	274	1,770	52	CA, EU, US	Feb 26, 2004	1997-07
Gemcitabine	Approved	Phase 4	438	225	398	1,996	52	CA, US	Aug 4, 2011	1995-02
Fludarabine	Approved	Phase 4	390	229	90	1,309	11	CA, US	Sep 24, 2002	1994-01
Dexamethasone	Approved	Phase 4	388	175	329	1,446	11	EU, US	Jun 20, 1962	1990-01
Capecitabine	Approved	Phase 4	354	183	329	1,352	47	CA, EU, US	Apr 30, 1998	1998-07
Venetoclax	Approved	Phase 4	349	195	71	576	18	CA, EU, US	Apr 11, 2016	Jul 11, 2007
Rituximab	Approved	Phase 4	335	143	247	1,358	37	CA, EU, US	Nov 26, 1997	May 8, 1993
Oxaliplatin	Approved	Phase 4	327	162	241	1,206	26	CA, US	Aug 7, 2009	1998-01
Docetaxel	Approved	Phase 4	314	160	436	1,701	75	CA, EU, US	Nov 27, 1995	1993-05
Durvalumab	Approved	Phase 4	292	114	91	640	29	CA, EU, US	May 1, 2017	Sep 5, 2012
Doxorubicin	Approved	Phase 4	287	125	372	1,353	41	CA, EU, US	Dec 23, 1987	1988-03
Fluorouracil	Approved	Phase 4	262	140	368	1,314	22	CA, US	Jul 29, 1970	1977-09
Atezolizumab	Approved	Phase 4	248	103	100	600	45	CA, EU, US	May 18, 2016	Oct 16, 2008
Lenalidomide	Approved	Phase 4	247	94	138	844	21	EU, US	Dec 27, 2005	2002-03
Etoposide	Approved	Phase 4	239	110	283	1,194	18	CA, US	Dec 31, 1984	1988-03
Pemetrexed	Approved	Phase 4	237	117	200	826	102	CA, EU, US	Feb 4, 2004	1997-09
Prednisone	Approved	Phase 4	212	84	203	825	1	US	Jan 17, 1972	1989-02
Tislelizumab	Approved	Phase 4	210	107	58	396	17	CA, EU, US	Sep 15, 2023	Jun 2, 2015
Ipilimumab	Approved	Phase 4	200	78	63	667	30	CA, EU, US	Mar 25, 2011	2001-10
Temozolomide	Approved	Phase 4	198	99	78	770	68	CA, EU, US	Jan 26, 1999	1997-07
Cytarabine	Approved	Phase 4	197	105	198	1,004	23	CA, EU, US	Jun 4, 1990	1986-11
Vincristine	Approved	Phase 4	196	86	261	862	8	CA, US	Apr 19, 1988	1977-09
Azacitidine	Approved	Phase 4	192	113	57	514	31	CA, EU, US	May 19, 2004	1999-07
Toripalimab	Approved	Phase 4	186	106	34	325	4	CA, EU, US	Oct 27, 2023	2016-08
Irinotecan	Approved	Phase 4	181	99	140	958	28	CA, EU, US	Jun 14, 1996	1995-11
Trastuzumab	Approved	Phase 4	175	78	171	758	47	CA, EU, US	Sep 25, 1998	1998-04
Lenvatinib	Approved	Phase 4	168	78	58	369	25	CA, EU, US	Feb 13, 2015	2005-07
Olaparib	Approved	Phase 4	155	59	41	343	26	CA, EU, US	Dec 16, 2014	Jun 15, 2007
Cetuximab	Approved	Phase 4	153	91	98	766	15	CA, EU, US	Feb 12, 2004	1999-04
Leucovorin	Approved	Phase 4	141	68	185	756	3	US	Feb 3, 2026	1989-02
Daratumumab	Approved	Phase 4	139	61	57	254	19	CA, EU, US	Nov 16, 2015	Jan 31, 2012
Fulvestrant	Approved	Phase 4	138	65	67	371	37	CA, EU, US	Apr 25, 2002	1997-05
Cemiplimab	Approved	Phase 3	130	70	15	183	18	CA, EU, US	Sep 28, 2018	Mar 1, 2010
Methotrexate	Approved	Phase 4	128	71	175	719	87	CA, EU, US	Aug 10, 1959	1986-05
Bortezomib	Approved	Phase 4	128	52	104	699	51	CA, EU, US	May 13, 2003	1999-07
Obinutuzumab	Approved	Phase 4	124	53	36	251	13	CA, EU, US	Nov 1, 2013	2007-09
Osimertinib	Approved	Phase 4	119	49	36	206	16	CA, EU, US	Nov 13, 2015	Mar 4, 2013
Letrozole	Approved	Phase 4	113	58	110	409	51	CA, US	Jul 25, 1997	1998-03
Cabozantinib	Approved	Phase 4	104	50	28	239	20	CA, EU, US	Nov 29, 2012	2005-09
Pertuzumab	Approved	Phase 4	104	43	62	230	17	CA, EU, US	Jun 8, 2012	2001-11
Palbociclib	Approved	Phase 4	103	40	29	256	40	CA, EU, US	Feb 3, 2015	2004-09
Abemaciclib	Approved	Phase 4	103	60	21	186	18	CA, EU, US	Sep 28, 2017	Dec 7, 2009
Enzalutamide	Approved	Phase 4	99	50	48	274	35	CA, EU, US	Aug 31, 2012	Jul 8, 2005
Pomalidomide	Approved	Phase 4	95	42	44	230	12	EU, US	Feb 8, 2013	2003-09

Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.